^
Association details:
| Biomarker: | ABCB1 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
Published date:
02/16/2021
Excerpt:
The SW620/GEDA cell line was proved to resistant to gedatolisib and a series of chemotherapeutic drugs, except cisplatin. The ABCB1 and ABCG2 were observed overexpression in SW620/GEDA cell line….These findings suggest that overexpression of ABCB1 and ABCG2 may restrict the efficacy of gedatolisib in colorectal cancer cells...
Secondary therapy:
everolimus + letrozole
DOI:
10.1186/s12935-021-01800-7
